Central and Eastern European Healthcare Markets Hold Strong Potential for Growth Despite the Economic Slowdown, Says Frost &...(boast of an unmet demand for pharmaceuti...),Health

CEE pharmaceutical and medical devices markets are on average 1.5 to five times smaller in value terms per capita than the Western European ones. The improving economic position of countries in the region is resulting in a better quality of life, higher life expectancy and a consequent demand for efficient healthcare services by the ageing population.

However, the markets will be restrained by incoherent reforms of the healthcare system and volatile regulatory requirements imposed on market participants.

"For instance, compulsory fees for drug prescription in the Czech Republic and Hungary, a new pharmaceutical pricing scheme in Slovakia, and mandatory labelling of all medicaments in Cyrillic alphabet in Bulgaria, will adversely affect the market in the short-term," explains Lehkyy. "These measures imply an additional cost pressure either on consumers or drug-manufacturers and will have an adverse effect on the development of pharmaceutical markets in these countries."

Therefore, timely and effective response from government authorities will be crucial to the favourable development of the healthcare market in CEE.

Overview of Pharmaceutical and Medical Devices Industry in Central and Eastern Europe is part of the Pharmaceuticals & Biotechnology Growth Partnership Services programme, which also includes research in the following markets: Global Active Pharmaceutical Ingredients Market Outlook, European Biomarker Analysis Market, and Emerging Therapeutic Segments in the European Biopharmaceutical Market. All research services included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants.

Frost & Sullivan, the Growth Partnership Company, enables client
'/>"/>